IMS Health and Foundation Medicine have entered a partnership to advance the understanding and effectiveness of precision therapies to treat cancer.

Under the collaboration, IMS Health’s Real-World Evidence (RWE) platform will combine with Foundation Medicine’s comprehensive cancer genomic profiles knowledgebase.

The offering will enable commercial, medical and outcomes research teams in biopharma and life sciences companies to gain insights to rapidly assess health outcomes and effectiveness.

"As life sciences companies look to deploy new, targeted therapies that address the unique molecular drivers of specific cancers, it has become increasingly important for them to better understand unmet needs."

This will help improve cancer care by better connecting patients to the right targeted therapies at the right time.

IMS Health Real-World Evidence Solutions vice-president and general manager Jon Resnick said: "As life sciences companies look to deploy new, targeted therapies that address the unique molecular drivers of specific cancers, it has become increasingly important for them to better understand unmet needs, treatment decisions and outcomes for patient populations living with those cancers.

"This collaboration with Foundation Medicine extends our Real-World Evidence platform, uniquely linking claims, EMR and biomarker data at the anonymous patient level to drive a complete understanding of the oncology patient journey and improve clinical development and commercialisation strategies."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The oncologic insights will be powered by IMS Health’s scalable and secure RWE platform, Evidence 360 and FoundationCORE, a molecular information knowledgebase.

Evidence 360 helps clients extract, analyse and visualise real-world data to better understand and measure healthcare outcomes.

FoundationCORE contains comprehensive cancer genomic information and insights from more than 43,000 clinical cases profiled by Foundation Medicine.